Harvard Health Letter

Breakthrough breast cancer drug

A new drug for advanced-stage HER2-positive breast cancer is providing hope. T-DM1 is effective in women who've already had their cancer progress despite prior therapies and it's remarkably low in side effects.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In